|
Mutation Information
|
Mutation Site
|
L80I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.L80I+rt.M204I |
|
Relevant Drug
|
lamivudine (LAM) |
|
Country
|
beijing;China |
Literature Information
|
PubMed PMID
|
22398037
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2012 |
|
Journal
|
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology |
|
Title
|
The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation. |
|
Author
|
Ji D,Liu Y,Li L,Xu Z,Si LL,Dai JZ,Li X,Wang L,Yao Z,Xin SJ,Chen GF,Xu D |
|
Evidence
|
The rtM204I, rtM204I + L229F, and rtM204I + L80I strains were all dramatically resistant to LAM, but remained susceptible to ADV, ETV, and TDF.
|
|
|
HBV Mutation Detail Information